Beyond Sequential Screening
Beyond Sequential Screening
Courtesy of Vitra Bioscience The unprecedented number of promising new drug candidates coming out of drug-discovery efforts has not translated into a commensurate increase in new drugs available at the pharmacy. Drug development backlogs arise, in part, because compounds are tested sequentially, one variable at a time, says Andrew Whiteley, CEO of Vitra Bioscience, Mountain View, Calif. What's needed, he says, is a more streamlined approach that allows scientists to look at the effects of dru